Selective internal radiotherapy (SIRT) of hepatic tumors: how to deal with the cystic artery

Cardiovasc Intervent Radiol. 2013 Aug;36(4):1015-22. doi: 10.1007/s00270-012-0474-1. Epub 2012 Sep 15.

Abstract

Purpose: Selective internal radiotherapy (SIRT) with the beta emitter yttrium-90 (Y90) is a rapidly developing therapy option for unresectable liver malignancies. Nontarget irradiation of the gallbladder is a complication of SIRT. Thus, we aimed to assess different strategies to avoid infusion of Y90 into the cystic artery (CA).

Methods: After hepatic digital subtraction angiography and administration of technetium-99m-labeled human serum albumin ((99)mTc-HSA), 295 patients with primary or secondary liver tumors underwent single-photon emission computed tomography/computed tomography (SPECT/CT). Different measures were taken before repeated Y90 mapping and SIRT to avoid unintended influx into the CA where necessary. Clinical symptoms, including pain, fever, or a positive Murphy sign, were assessed during patient follow-up.

Results: A significant (99)mTc-HSA accumulation in the gallbladder wall (higher (99)mTc-HSA uptake than in normal liver tissue) was seen in 20 patients. The following measures were taken to avoid unintended influx into the CA: temporary/permanent occlusion of the CA with gelfoam (n = 5)/microcoil (n = 1), induction of vasospasm with a microwire (n = 4), or altering catheter position (n = 10). Clinical signs of cholecystitis were observed in only one patient after temporary CA occlusion with gelfoam and were successfully treated by antibiotics. Cholecystectomy was not required for any patient.

Conclusion: It is important to identify possible nontarget irradiation of the gallbladder. The risk for radiation-induced cholecystitis can be easily minimized by temporary or permanent CA embolization, vasospasm induction, or altering the catheter position.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Angiography, Digital Subtraction
  • Brachytherapy / methods*
  • Carcinoma, Hepatocellular / diagnosis
  • Carcinoma, Hepatocellular / mortality
  • Carcinoma, Hepatocellular / radiotherapy*
  • Cohort Studies
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Hepatic Artery / diagnostic imaging
  • Hepatic Artery / pathology
  • Humans
  • Liver Neoplasms / diagnosis
  • Liver Neoplasms / mortality
  • Liver Neoplasms / radiotherapy*
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Assessment
  • Survival Rate
  • Technetium Tc 99m Aggregated Albumin / therapeutic use*
  • Tomography, Emission-Computed, Single-Photon / methods
  • Treatment Outcome
  • Yttrium Radioisotopes

Substances

  • Technetium Tc 99m Aggregated Albumin
  • Yttrium Radioisotopes